Overall, the large-cap biopharmaceutical group has strong balance sheets, makes solid investment decisions, and distributes cash appropriately. All of this supports the ability to develop the next ...
Interest in private-market allocations appears to continue its steady ascent in 2025. Historical returns and diversification potential are attracting a wide variety of asset owners, who are accessing ...
Results that may be inaccessible to you are currently showing.
Hide inaccessible results